These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8923513)

  • 1. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
    Vertongen P; Camby I; Darro F; Kiss R; Robberecht P
    Neuropeptides; 1996 Oct; 30(5):491-6. PubMed ID: 8923513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
    Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
    Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
    Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
    Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat aortic smooth-muscle cell proliferation is bidirectionally regulated in a cell cycle-dependent manner via PACAP/VIP type 2 receptor.
    Miyata A; Sato K; Hino J; Tamakawa H; Matsuo H; Kangawa K
    Ann N Y Acad Sci; 1998 Dec; 865():73-81. PubMed ID: 9927999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
    Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
    Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
    Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
    Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
    Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
    Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential alternative splicing of PACAP receptor in pituitary cell subpopulations.
    Vertongen P; Velkeniers B; Hooghe-Peters E; Robberecht P
    Mol Cell Endocrinol; 1995 Sep; 113(2):131-5. PubMed ID: 8674820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.